SCHEMBL16340671

SCHEMBL16340671

CC(=O)N[C@H]1CCNC(=O)C[C@@H](C(C)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSLP Q969D9 16/20 0.57
TUBB4A P04350 2/20 0.50
TUBB P07437 2/20 0.50
TUBA3C P0DPH7 2/20 0.50
TUBA1B P68363 2/20 0.50
TUBA4A P68366 2/20 0.50
TUBB4B P68371 2/20 0.50
TUBB3 Q13509 2/20 0.50
TUBB2A Q13885 2/20 0.50
TUBB8 Q3ZCM7 2/20 0.50
TUBA3E Q6PEY2 2/20 0.50
TUBA1A Q71U36 2/20 0.50
TUBA1C Q9BQE3 2/20 0.50
TUBB6 Q9BUF5 2/20 0.50
TUBB2B Q9BVA1 2/20 0.50
TUBB1 Q9H4B7 2/20 0.50
MC4R P32245 2/20 0.48
MC1R Q01726 2/20 0.48
MC5R P33032 1/20 0.48
MC3R P41968 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16340418 0.97 TSLP (0.56) TSLPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL16340575 0.96 TSLP (0.56) TSLPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL16340684 0.95 TSLP (0.57) TSLPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL16340715 0.95 TSLP (0.57) TSLPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL16340710 0.94 TSLP (0.58) TSLPMC4RMC1RMC5RMC3R
SCHEMBL16340706 0.94 TSLP (0.57) TSLPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL16340416 0.94 TSLP (0.57) TSLPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL16340382 0.93 TSLP (0.56) TSLPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL16340729 0.92 TSLP (0.58) TSLPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL16340714 0.92 TSLP (0.57) TSLPTUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130012432-A1 Peptides for Treatment of Obesity NOVO NORDISK A/S (DK) 2013-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012432-A1 Peptides for Treatment of Obesity MC4R, GIPR, MC3R TSLP 177/4885TUBB4A 3592/4885TUBB 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.